+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Malignant Pleural Mesothelioma (MPM)- Epidemiology Forecast to 2030

  • ID: 5135437
  • Report
  • August 2020
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2
The ‘Malignant Pleural Mesothelioma (MPM)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted MPM epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Malignant Pleural Mesothelioma (MPM) Understanding

Mesothelioma is a rare, aggressive form of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen or heart. Pleural mesothelioma is a cancer of the pleura, which is the mesothelium surrounding the lungs and it is the most common type of mesothelioma, accounting for 80 - 90% of all diagnosed cases. Because males are exposed to asbestos more often, they are more likely to be diagnosed with mesothelioma. The main risk factor for pleural mesothelioma is exposure to asbestos. Asbestos is a group of minerals that occur naturally as bundles of tiny fibers. These fibers are found in soil and rocks in many parts of the world. When asbestos fibers in the air are inhaled, they can get into the lungs. Fibers that stay in the lungs can travel to the ends of the small airways and enter the pleural lining of the lung and chest wall. The initial clinical presentation of mesothelioma may be dyspnea, generally associated with developing pleural effusion. Pleural pain, not related to breathing movements, is also a common manifestation. Weight loss and other symptoms are rare in the early stages, but as the condition advances, marked hemithorax retraction is often observed, and pain becomes particularly intense and persistent. Standard diagnostic workup in patients with MPM includes Chest X-ray, computed tomography (CT) scan of the chest and upper abdomen, PET, MRI to define the extension of the disease. Invasive procedures are required to obtain specimens for a definitive histological and bio-molecular diagnosis. Additional investigations include blood markers and pulmonary function tests.

Epidemiology Perspective

The MPM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MPM epidemiology data are studied through MPM possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted MPM epidemiology [segmented as Total Incidence of Mesothelioma, Total Incident Cases of MPM, Total Incident Cases of MPM Segmented by Age and Gender, Total Type-specific Cases of MPM, Total Incident Cases of MPM by Stages, and Treated Patient Pool of MPM] scenario of MPM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

MPM Detailed Epidemiology Segmentation
  • The total Incident cases of MPM in the 7MM were observed to be 11,431 cases in 2017 which are estimated to decline during the study period (2017-2030
  • Mesothelioma incidence rates in most of the 7MM countries (except Spain and Japan) are in the declining trend due to reduced population-wide exposure to asbestos.
  • In EU-5 countries, the highest number of incident cases of MPM was found in the United Kingdom with 2,495 cases in 2017, followed by Germany and Italy.
  • Epithelial mesothelioma cells are the most common type of MPM and respond the best to treatment
  • In age-specific cases of MPM, the most number of cases were observed in elder people (more than 80% cases in people age 60 years and above) because mesothelioma carries an unusually long latency period of 20 to 50 years.
Scope of the Report
  • The MPM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The MPM Report and Model provide an overview of the risk factors and global trends of MPM in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
  • The report provides insight about the historical and forecasted patient pool of MPM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of MPM.
  • The report provides the segmentation of the MPM epidemiology by total Incidence of MPM in the 7MM.
  • The report provides the segmentation of the MPM epidemiology by Age and Gender in the 7MM.
  • The report provides the segmentation of the MPM epidemiology by Type and Stages in the 7MM.
  • The report provides the segmentation of the MPM epidemiology by Treated Patient Pool of MPM in the 7MM.
Report Highlights
  • 11-Year Forecast of MPM epidemiology
  • 7MM Coverage
  • Total Incident Cases of Mesothelioma in the 7MM
  • Total Incident Cases of MPM in the 7MM
  • Incident Cases of MPM according to segmentation: Age, Gender, Types, and Stages
  • Treated cases of MPM
KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over MPM scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to MPM ?
  • What are the key findings pertaining to the Malignant Pleural Mesothelioma epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Malignant Pleural Mesothelioma across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Malignant Pleural Mesothelioma?
  • What % of MPM patients diagnosed with the most advanced stage of cancer at diagnosis? And what % of patients with local or regional stage are progressing to distant stage?
Reasons to buy

The MPM Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global MPM market
  • Quantify patient populations in the global MPM market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MPM therapeutics in each of the markets covered
  • Understand the magnitude of MPM population by its severity
  • The MPM epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The MPM Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Total Incident cases of MPM in the United States was assessed to be 2,627 in 2017, and are expected to decline during the study period. Among the European 5 countries, the United Kingdom had the highest Incident population of MPM. On the other hand, Spain had the lowest incident cases of MPM in 2017.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Executive Summary of Malignant Pleural Mesothelioma (MPM)

3. Malignant Pleural Mesothelioma: Market Overview at a Glance

4. Malignant Pleural Mesothelioma (MPM): Disease Background and Overview
4.1. Introduction
4.2. Malignant Pleural Mesothelioma (MPM)
4.2.1. Signs and Symptoms of MPM
4.2.2. Risk Factors and Causes of MPM
4.2.3. Pathophysiology of MPM

5. Diagnosis of MPM
5.1. Chest X-ray
5.2. Thoracic ultrasound (US)
5.3. CT scan
5.4. Magnetic resonance imaging (MRI)
5.5. PET-CT scan
5.6. Thoracentesis
5.7. Pleural Biopsy
5.7.1. CT-guided Core Biopsy
5.7.2. Abrams Needle Biopsy
5.7.3. Open Biopsy
5.7.4. Thoracoscopic Biopsy
5.8. SMRP Blood Test
5.9. Histological Diagnosis of MPM
5.10. Biomarkers in the Diagnosis of MPM
5.11. Stages of MPM
5.11.1. The TNM Staging System

6. Epidemiology and Patient Population
6.1. Epidemiology Key Findings
6.2. Assumptions and Rationale: 7MM

7. Epidemiology Scenario: 7MM
7.1. Total Incident Cases of Mesothelioma in the 7MM
7.2. Total Incident Cases of MPM in the 7MM
7.3. Gender-specific Cases of MPM in the 7MM
7.4. Age-specific Cases of MPM in the 7MM
7.5. Type-specific Cases of MPM in the 7MM
7.6. Total Incident Cases of MPM by Stages in the 7MM
7.7. Treated cases of MPM in the 7MM

8. The United States Epidemiology
8.1. Total Incident Cases of MPM in the US
8.2. Gender-specific Cases of MPM in the US
8.3. Age-specific Cases of MPM in the US
8.4. Type-specific Cases of MPM in the US
8.5. Total Incident Cases of MPM by Stages in the US
8.6. Treated cases of MPM in the US

9. EU-5 Epidemiology
9.1. Germany
9.1.1. Total Incident Cases of MPM in Germany
9.1.2. Gender-specific Cases of MPM in Germany
9.1.3. Age-specific Cases of MPM in Germany
9.1.4. Type-specific Cases of MPM in Germany
9.1.5. Total Incident Cases of MPM by Stages in Germany
9.1.6. Treated cases of MPM in Germany
9.2. France
9.2.1. Total Incident Cases of MPM in France
9.2.2. Gender-specific Cases of MPM in France
9.2.3. Age-specific Cases of MPM in France
9.2.4. Type-specific Cases of MPM in France
9.2.5. Total Incident Cases of MPM by Stages in France
9.2.6. Treated cases of MPM in France
9.3. Italy
9.3.1. Total Incident Cases of MPM in Italy
9.3.2. Gender-specific Cases of MPM in Italy
9.3.3. Age-specific Cases of MPM in Italy
9.3.4. Type-specific Cases of MPM in Italy
9.3.5. Total Incident Cases of MPM by Stages in Italy
9.3.6. Treated cases of MPM in Italy
9.4. Spain
9.4.1. Total Incident Cases of MPM in Spain
9.4.2. Gender-specific Cases of MPM in Spain
9.4.3. Age-specific Cases of MPM in Spain
9.4.4. Type-specific Cases of MPM in Spain
9.4.5. Total Incident Cases of MPM by Stages in Spain
9.4.6. Treated cases of MPM in Spain
9.5. The United Kingdom
9.5.1. Total Incident Cases of MPM in the United Kingdom
9.5.2. Gender-specific Cases of MPM in the United Kingdom
9.5.3. Age-specific Cases of MPM in the United Kingdom
9.5.4. Type-specific Cases of MPM in the United Kingdom
9.5.5. Total Incident Cases of MPM by Stages in the United Kingdom
9.5.6. Treated cases of MPM in the United Kingdom

10. Japan Epidemiology
10.1. Total Incident Cases of MPM in Japan
10.2. Gender-specific Cases of MPM in Japan
10.3. Age-specific Cases of MPM in Japan
10.4. Type-specific Cases of MPM in Japan
10.5. Total Incident Cases of MPM by Stages in Japan
10.6. Treated cases of MPM in Japan

11. Appendix
11.1. Bibliography
11.2. Report Methodology

12. Publisher Capabilities

13. Disclaimer

14. About the Publisher

List of Tables
Table 1: Summary of MPM Epidemiology, and Key Events (2017–2030)
Table 2: Immunohistochemical Markers for Differentiating Epithelioid Mesothelioma from Other Metastatic Pleural Tumors
Table 3: Immunohistochemical Markers for Differentiating Sarcomatous Mesothelioma from Squamous Cell or Transitional Cell Carcinoma.
Table 4: Stages of MPM
Table 5: Total Incident Cases of Mesothelioma in the 7MM (2017–2030)
Table 6: Total Incident cases of MPM in the 7MM (2017–2030)
Table 7: Gender-specific Cases of MPM in the 7MM (2017–2030)
Table 8: Age-specific Cases of MPM in the 7MM (2017–2030)
Table 9: Type-specific Cases of MPM in the 7MM (2017–2030)
Table 10: Total Incident Cases of MPM by Stages in the 7MM (2017–2030)
Table 11: Treated cases of MPM in the 7MM (2017–2030)
Table 12: Total Incident cases of MPM in the US (2017–2030)
Table 13: Gender-specific Cases of MPM in the US (2017–2030)
Table 14: Age-specific Cases of MPM in the US (2017–2030)
Table 15: Type-specific Cases of MPM in the US (2017–2030)
Table 16: Total Incident Cases of MPM by Stages in the US (2017–2030)
Table 17: Treated cases of MPM in the US (2017–2030)
Table 18: Total Incident cases of MPM in Germany (2017–2030)
Table 19: Gender-specific Cases of MPM in Germany (2017–2030)
Table 20: Age-specific Cases of MPM in Germany (2017–2030)
Table 21: Type-specific Cases of MPM in Germany (2017–2030)
Table 22: Total Incident Cases of MPM by Stages in Germany (2017–2030)
Table 23: Treated cases of MPM in Germany (2017–2030)
Table 24: Total Incident cases of MPM in France (2017–2030)
Table 25: Gender-specific Cases of MPM in France (2017–2030)
Table 26: Age-specific Cases of MPM in France (2017–2030)
Table 27: Type-specific Cases of MPM France (2017–2030)
Table 28: Total Incident Cases of MPM by Stages in France (2017–2030)
Table 29: Treated cases of MPM in Germany (2017–2030)
Table 30: Total Incident cases of MPM in Italy (2017–2030)
Table 31: Gender-specific Cases of MPM in Italy (2017–2030)
Table 32: Age-specific Cases of MPM in Italy (2017–2030)
Table 33: Type-specific Cases of MPM in Italy (2017–2030)
Table 34: Total Incident Cases of MPM by Stages in Italy (2017–2030)
Table 35: Treated cases of MPM in Italy (2017–2030)
Table 36: Total Incident cases of MPM in Spain (2017–2030)
Table 37: Gender-specific Cases of MPM in Spain (2017–2030)
Table 38: Age-specific Cases of MPM in Spain (2017–2030)
Table 39: Type-specific Cases of MPM in Spain (2017–2030)
Table 40: Total Incident Cases of MPM by Stages in Spain (2017–2030)
Table 41: Treated cases of MPM in Spain (2017–2030)
Table 42: Total Incident cases of MPM in the United Kingdom (2017–2030)
Table 43: Gender-specific Cases of MPM in the United Kingdom (2017–2030)
Table 44: Age-specific Cases of MPM in the United Kingdom (2017–2030)
Table 45: Type-specific Cases of MPM in the United Kingdom (2017–2030)
Table 46: Total Incident Cases of MPM by Stages in the United Kingdom (2017–2030)
Table 47: Treated cases of MPM in the UK (2017–2030)
Table 48: Total Incident cases of MPM in Japan (2017–2030)
Table 49: Gender-specific Cases of MPM in Japan (2017–2030)
Table 50: Age-specific Cases of MPM in Japan (2017–2030)
Table 51: Type-specific Cases of MPM in Japan (2017–2030)
Table 52: Total Incident Cases of MPM by Stages in Japan (2017–2030)
Table 53: Treated cases of MPM in Japan (2017–2030)

List of Figures
Figure 1: Malignant Pleural Mesothelioma (MPM) SWOT Analysis
Figure 2: Parts of Lung Affected by Pleural Mesothelioma
Figure 3: Types of MPM
Figure 4: Signs and Symptoms of MPM
Figure 5: Risks Factors of MPM
Figure 6: Pathophysiology of MPM
Figure 7: Hypotheses on Mechanisms that Lead to Neoplastic Transformation of Mesothelial Cells
Figure 8: Algorithm for the Work Up of the Asbestos-exposed Individual who Presents with New Symptoms
Figure 9: Poster Anterior CXR Follow-up Images of Progressive MPM in a 61-year-old Female
Figure 10: Risks Factors of MPM
Figure 11: Global Heat Map of Mesothelioma
Figure 12: Total Incident Cases of Mesothelioma in the 7MM (2017–2030)
Figure 13: Total Incident cases of MPM in the 7MM (2017–2030)
Figure 14: Gender-specific Cases of MPM in the 7MM (2017–2030)
Figure 15: Age-specific Cases of MPM in the 7MM (2017–2030)
Figure 16: Type-specific Cases of MPM in the 7MM (2017–2030)
Figure 17: Total Incident Cases of MPM by Stages in the 7MM (2017–2030)
Figure 18: Treated cases of MPM in the 7MM (2017–2030)
Figure 19: Total Incident cases of MPM in the US (2017–2030)
Figure 20: Gender-specific Cases of MPM in the US (2017–2030)
Figure 21: Age-specific Cases of MPM in the US (2017–2030)
Figure 22: Type-specific Cases of MPM in the US (2017–2030)
Figure 23: Total Incident Cases of MPM by Stages in the US (2017–2030)
Figure 24: Treated cases of MPM in the US (2017–2030)
Figure 25: Total Incident cases of MPM in Germany (2017–2030)
Figure 26: Gender-specific Cases of MPM in Germany (2017–2030)
Figure 27: Age-specific Cases of MPM in Germany (2017–2030)
Figure 28: Type-specific Cases of MPM in Germany (2017–2030)
Figure 29: Total Incident Cases of MPM by Stages in Germany (2017–2030)
Figure 30: Treated cases of MPM in Germany (2017–2030)
Figure 31: Total Incident cases of MPM in France (2017–2030)
Figure 32: Gender-specific Cases of MPM in France (2017–2030)
Figure 33: Age-specific Cases of MPM in France (2017–2030)
Figure 34: Type-specific Cases of MPM France (2017–2030)
Figure 35: Total Incident Cases of MPM by Stages in France (2017–2030)
Figure 36: Treated cases of MPM in France (2017–2030)
Figure 37: Total Incident cases of MPM in Italy (2017–2030)
Figure 38: Gender-specific Cases of MPM in Italy (2017–2030)
Figure 39: Age-specific Cases of MPM in Italy (2017–2030)
Figure 40: Type-specific Cases of MPM in Italy (2017–2030)
Figure 41: Total Incident Cases of MPM by Stages in Italy (2017–2030)
Figure 42: Treated cases of MPM in Italy (2017–2030)
Figure 43: Total Incident cases of MPM in Spain (2017–2030)
Figure 44: Gender-specific Cases of MPM in Spain (2017–2030)
Figure 45: Age-specific Cases of MPM in Spain (2017–2030)
Figure 46: Type-specific Cases of MPM in Spain (2017–2030)
Figure 47: Total Incident Cases of MPM by Stages in Spain (2017–2030)
Figure 48: Treated cases of MPM in Spain (2017–2030)
Figure 49: Total Incident cases of MPM in the United Kingdom (2017–2030)
Figure 50: Gender-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 51: Age-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 52: Type-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 53: Total Incident Cases of MPM by Stages in the United Kingdom (2017–2030)
Figure 54: Treated cases of MPM in the United Kingdom (2017–2030)
Figure 55: Total Incident cases of MPM in Japan (2017–2030)
Figure 56: Gender-specific Cases of MPM in Japan (2017–2030)
Figure 57: Age-specific Cases of MPM in Japan (2017–2030)
Figure 58: Type-specific Cases of MPM in Japan (2017–2030)
Figure 59: Total Incident Cases of MPM by Stages in Japan (2017–2030)
Figure 60: Treated cases of MPM in Japan (2017–2030)
Note: Product cover images may vary from those shown
Adroll
adroll